Greenstone intros authorized generic version of Vibramycin Hyclate
Cardinal Health: Patient-reported outcomes informs patient-centric care
- One study (abstract #56252 presented in poster session PHS87) used PRO to demonstrate that rheumatologists significantly underestimated the negative impact of RA disease burden and treatment on their patients’ sense of well-being. Understanding this disparity in perceptions can help physicians make effective treatment decisions that lessen the burden on patients, and can sometimes also reduce the costs of their care;
- Another study (abstract #56274 presented in poster session PHS88) showed that PRO can be critical to identifying and managing medication access and adherence challenges for high-cost specialty drugs. Of a total of 239 oncology and rheumatology patients who were contacted at the time of their initial prescription to provide patient reported outcomes, 28% were identified as having problems that either restricted access or adherence to the drug. Armed with this information, interventions and support services were provided to address those challenges. With the support of these interventions, a medication possession ration exceeding 95% was achieved – enabling nearly all patients to initiate or continue treatment; and
- A third study (abstract #56177 presented in poster session PHS88) proved the feasibility of collecting PRO at the point of care. In the clinical study involving 3,185 RA patients, PRO data was captured during 90% of physician visits through use of the PathWare decision support tool. The participating physicians were then able to utilize the data to inform real-time treatment decisions at the point of care.
NACDS further bolsters government affairs team with new public health policy expert
ARLINGTON, Va. — The National Association of Chain Drug Stores has announced the hiring of Deepti A. Loharikar as director, federal and state public policy.
Loharikar joined NACDS on May 11. She will report to Kevin Nicholson, VP, public affairs and regulatory affairs.
In her role at NACDS, Loharikar will provide policy expertise on pharmacy issues at the state and federal levels. She will serve as the public policy expert on drug and patient safety, Internet pharmacies, consumer drug safety initiatives and related issues, providing policy analysis on proposed and enacted legislation and regulations. Loharikar will also prepare and deliver testimony and regulatory comments, and develop other advocacy materials in support of key issues that impact chain pharmacy.
“No stranger to the intersection of law and public health policy, Deepti brings a wealth of experience to her position at NACDS,” state NACDS president and CEO Steve Anderson. “Deepti’s expertise in health policy, combined with her legal background, makes her an effective legislative and regulatory advocate for chain pharmacy. We welcome her to NACDS’ already highly-talented government affairs team.”
Loharikar comes to NACDS from the Department of Health and Human Services where she oversaw the development and implementation of long-term strategies for the consumer-oriented and operated plan (CO-OP) insurance program. In addition, she previously served as a health policy analyst for the Federal Office of Rural Health Policy at HHS. Prior to her work for the federal government, Loharikar practiced law at a law firm in New Jersey and with the Department of Justice Washington, D.C.